2nd Cell & Gene Therapy Pricing & Reimbursement Summit

The 2nd Cell & Gene Therapy Pricing & Reimbursement Summit will take place from May 27 to 29, 2025, at the Marriott Washington Capitol Hill in Washington, DC. This summit aims to address the challenges in pricing, coverage, and payment frameworks that hinder global access to approved cell and gene therapies (CGTs). Attendees will engage in discussions on innovative payment models, stop-loss and reinsurance programs, and strategies to ensure coverage and uptake of commercialized therapies. The event will also provide insights into recent CMS policy changes, including the Access Model, Medicaid Drug Rebate Program Final Rule, and proposed increases to inpatient CAR-T reimbursement rates.

The summit will feature a diverse lineup of speakers from leading pharmaceutical companies and organizations. Notable speakers include Francis Pang, Senior Vice President of Global Market Access & International Geographic Expansion at Orchard Therapeutics; Laura Okpala, Executive Director & Head of Reimbursement Policy & Government Affairs at Gilead Sciences; and Sabrina Aery, Executive Director of US Government Programs, US Field Access at Bristol Myers Squibb. Other distinguished speakers are Swaminathan Subramanian, Head of US Global Pricing & Contracting at Regeneron Pharmaceuticals, and Robert Rouse, Head of Market Access at CSL Behring. The event will also host representatives from academia, government agencies, commercial payers, and market access-specialist service providers, fostering a comprehensive dialogue on enhancing payer coverage and improving patient access to CGTs.